The multifaceted circulating endothelial cell in cancer: Towards marker and target identification

Nature Reviews Cancer

Volumn 6, Issue 11, 2006, Pages 835-845

  Bertolini, Francesco ^a   Shaked, Yuval ^b   Mancuso, Patrizia ^a   Kerbel, Robert S ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; CANCER; DISEASE MARKER; DRUG ACTIVITY; ENDOTHELIUM CELL; HEMATOPOIETIC CELL; ONCOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW;

ANGIOGENESIS INHIBITORS; ENDOTHELIUM, VASCULAR; HUMANS; KINETICS; NEOPLASMS; STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 33750286135     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1971     Document Type: Review

References (91)

1. Schrag, D. The price tag on progress - chemotherapy for colorectal cancer. N. Engl. J. Med. 351, 317-319 (2004).
2. Jain, R. K., Duda, D. G., Clark, J. W. & Loeffler, J. S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clin. Pract. Onco. 3, 24-40 (2006).
3. Schneider, M., Tjwa, M. & Carmeliet, P. A surrogate marker to monitor angiogenesis at last. Cancer Cell 7, 3-4 (2005).
4. Kerbel, R. S. & Folkman, J. Clinical translation of angiogenesis inhibitors. Nature Rev. Cancer 2, 727-739 (2002).
5. Hlatky, L., Hahnfeldt, P. & Folkman, J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl Cancer Inst. 94, 883-893 (2002).
6. Jain, R. K. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin. Oncol. 29 (Suppl. 16), 3-9 (2002).
7. Motzer, R. J. et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 (2006).
8. Morgan, B. et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 2, 3955-3964 (2003).
9. Hladovec, J. & Rossamn, P. Circulating endothelial cells isolated together with platelets and the experimental modification of their counts in rats. Thromb. Res. 3, 665-674 (1973).
10. Blann, A. D. et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb. Haemost. 93, 228-235 (2005).
11. Cines, D. B. et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91, 3527-3561 (1998).
12. Solovey A. et al. Circulating activated endothelial cells in sickle cell anemia. N. Engl. J. Med. 337, 1584-1590 (1997).
13. Moldovan, N. I., Moldovan, L. & Simionescu, N. Binding of vascular anticoagulant alpha (annexin V) to the aortic intima of the hypercholesterolemic rabbit. An autoradiographic study. Blood Coagul. Fibrinolysis. 5, 921-928 (1994).
14. Rajagopalan, S. et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 103, 3677-3683 (2004).
15. Rabascio, C. et al. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res. 64, 4373-4377 (2004).
16. Mancuso, P. et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97, 3658-3661 (2001).
17. Lin, Y., Weisdorf, D. J., Solovey, A. & Hebbel, R. P. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 105, 71-77 (2000). Suggested for the first time that most CECs originate from vessel walls and have limited growth capability, whereas a tiny CEC subpopulation - probably from the bone marrow - is responsible for most endothelial cell proliferative potential.
18. Asahara, T. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967 (1997).
19. Shi, Q. et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 92, 362-367 (1998). References 18 and 19 demonstrated the presence of CEPs able to generate new vessels in adult mammals.
20. Goon, P. K., Lip, G. Y., Boos, C. J., Stonelake, P. S. & Blann, A. D. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8, 79-88 (2006).
21. Solovey, A. N. et al. Identification and functional assessment of endothelial P1H12. J. Lab. Clin. Med. 5, 322-331 (2001).
22. Elshal, M. F., Khan, S. S., Takahashi, Y., Solomon, M. A. & McCoy, J. P. Jr. CD146 (Mel-CAM), an adhesion marker of endothelial cells, is a novel marker of lymphocyte subset activation in normal peripheral blood. Blood 106, 2923-2924 (2005).
23. Duda, D. G. et al. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J. Clin. Oncol. 24, 1449-1453 (2006).
24. Kim, I., Yilmaz, O. H. & Morrison, S. J. CD144 (VE-cadherin) is transiently expressed by fetal liver hematopoietic stem cells. Blood 106, 903-905 (2005).
25. Shaked, Y. et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7, 101-111 (2005). Showed a correlation between CECs/CEPs and 'gold standard' preclinical angiogenesis assays, and indicated how CEC and/or CEP measurement can help to define the OBD of anti-angiogenic drugs.
26. Mancuso, P. et al. Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108, 452-459 (2006). Indicated that an increase in apoptotic CEC count - probably from tumour vessels - predicts better survival in patients with breast cancer treated with metronomic chemotherapy.
27. Furstenberger, G. et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br. J. Cancer 94, 524-531 (2006).
28. Norden-Zfoni, A. et al. Levels of circulating endothelial cells (CECs) and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) with metastatic imatinib-resistant GIST. Clin. Cancer Res. 2006 (in the press).
29. +.
30. Rafii, S., Lyden, D., Benezra, R., Hattori, K. & Heissig, B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nature Rev. Cancer 2, 826-835 (2002).
31. Pelosi, E. et al. Identification of the hemangioblast in postnatal life. Blood 100, 3203-3208 (2002).
32. Bailey, A. S. et al. Transplanted adult hematopoietic stems cells differentiate into functional endothelial cells. Blood 103, 13-19 (2004).
33. Capillo, M. et al. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin. Cancer Res. 9, 377-382 (2003).
34. Lyden, D. et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med. 7, 1194-1201 (2001). The first proof-of-principle of the contribution of CEPs to cancer growth. Transplanted, marrow-derived CEPs were able to restore defective tumour angiogenesis and the growth of some types of cancer cell lines.
35. Carmeliet, P. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Med. 7, 575-583 (2001).
36. Garcia-Barros, M. et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155-1159 (2003).
37. De Palma, M., Venneri, M. A., Roca, C. & Naldini, L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nature Med. 9, 789-795 (2003).
38. Gothert, J. R. et al. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood 104, 1769-1777 (2004).
39. Ruzinova, M. B. et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell. 4, 277-289 (2003).
40. Duda, D. G. et al. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood 107, 2774-2776 (2006).
41. Peters, B. A. et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nature Med. 11, 261-262 (2005).
42. Spring, H. et al. Chemokines direct endothelial progenitors into tumor neovessels. Proc. Natl Acad. Sci. USA 102, 18111-18116 (2005).
43. Stoll, B. R., Migliorini, C., Kadambi, A., Munn, L. L. & Jain, R. K. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood 102, 2555-2561 (2003).
44. Shaked, Y. et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313, 1785-1787 (2006).
45. Tozer G. M., Kanthou, C. & Baguley, B. C. Disrupting tumour blood vessels. Nature Rev. Cancer 5, 423-435 (2005).
46. Bertolini, F. et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 63, 4342-4346 (2003).
47. Kerbel, R. S. Antiangiogenic therapy: A universal chemosensitization strategy for cancer? Science 312, 1171-1175 (2006).
48. Ingram, D. A. et al. Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells. Blood 105, 2783-2786 (2005).
49. Zengin, E. et al. Vascular wall resident progenitor cells: a source for postnatal vasculogenesis. Development 133, 1543-1551 (2006).
50. Rajantie, I. et al. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 104, 2084-2086 (2004).
51. Hristov, M., Erl, W., Linder, S. & Weber, P. C. Apoptotic bodies from endothelial cells enhance the number and initiate the differentiation of human endothelial progenitor cells in vitro. Blood 104, 2761-2766 (2004).
52. Massberg, S. et al. Platelets secrete stromal cell-derived factor 1α and recruit bone marrow-derived progenitor cell to arterial trombi in vivo. J. Exp. Med. 203, 1221-1233 (2006).
53. Jin, D. K. et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nature Med. 12, 557-567 (2006).
54. Jin, H. et al. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. J. Clin. Invest. 116, 652-662 (2006). Described a specific adhesion event (mediated by integrin α4β1 (VLA-4) and its receptors) that facilitates the homing of progenitor cells to cancer neovasculature.
55. Reiher, F. K. et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int. J. Cancer 98, 682-689 (2002).
56. Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59, 5209-5218 (1999).
57. Monestiroli S. et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 61, 4341-4344 (2001).
58. Schuch, G. et al. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res. 63, 8345-8350 (2003).
59. Zhang, H. et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 105, 3286-3294 (2005).
60. Shaked, Y. et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood. 106, 3058-3061 (2005).
61. Celik, I. et al. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res. 65, 11044-11050 (2005).
62. Yee, K. W. et al. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. 11, 6615-6624 (2005).
63. Butzal, M. et al. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp. Cell Res. 300, 65-71 (2004).
64. Kerbel, R. S. & Kamen, B. A. The anti-angiogenic basis of metronomic chemotherapy. Nature Rev. Cancer. 4, 423-436 (2004).
65. Beaudry, P. et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin. Cancer Res. 11, 3514-3522 (2005).
66. Colleoni, M. et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 13, 73-80 (2002).
67. Colleoni, M. et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann. Oncol. 17, 232-238 (2006).
68. Jain, R. K. Molecular regulation of vessel maturation. Nature Med. 9, 685-693 (2003).
69. Kerbel, R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13, 31-36 (1991).
70. Hida, K. et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res. 64, 8249-8255 (2004).
71. Rigolin, G. M. et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 107, 2531-2535 (2006).
72. Streubel, B. et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N. Engl. J. Med. 351, 250-259 (2004).
73. Gunsilius, E. et al. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 355, 1688-1691 (2000).
74. van Heeckeren, W. J. et al. Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J. Clin. Oncol. 24, 1485-1488 (2006).
75. Tuma, R. S. Accrual delayed in adjuvant bevacizumab trial. J. Natl. Cancer Inst. 98, 439-440 (2006).
76. Beerepoot, L. V. et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J. Clin. Oncol. 24, 1491-1498 (2006).
77. Ferrari, N., Glod, J., Lee, J., Kobiler, D & Fine, H. A. Bone marrow-derived, endothelial progenitor-like cells as angiogenesis-selective gene-targeting vectors. Gene Ther. 10, 647-656 (2003).
78. Arbab, A. S. et al. Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells trafficking to sites of tumor angiogenesis. Stem Cells 24, 671-678 (2006).
79. Dignat-George, F. & Sampol, J. Circulating endothelial cells in vascular disorders: new insights into an old concept. Eur. J. Haematol. 65, 215-220 (2000).
80. Woywodt, A. et al. Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol. J. Thromb. Haemost. 4, 671-677 (2006).
81. Werner, N. et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353, 999-1007 (2005).
82. Rosenzweig, A. Circulating endothelial progenitors - cells as biomarkers. N. Engl. J. Med. 353, 1055-1057 (2005).
83. Aicher, A. et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nature Med. 9, 1370-1376 (2003)
84. Tateishi-Yumana, E. et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 360, 427-435 (2002).
85. Meyer, G. P. et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 113, 1287-1294 (2006).
86. Schachinger, V. et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J. Am. Coll. Cardiol. 44, 1690-1699 (2004).
87. Conejo-Garcia, J. R. et al. Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A. Nature Med. 10, 950-958 (2004).
88. Grunewald, M. et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124, 175-189 (2006).
89. De Palma, M. et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211-226 (2005).
90. Udagawa, T., Puder, M., Wood, M., Schaefe, B. C. & D'Amato, R. J. Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells. FASEB J. 20, 95-102 (2006).
91. Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820-827 (2005).